Company Presentations
BioVie Company Overview
Developing Transformative Therapies to Overcome Chronic Debilitating Diseases
Corporate Presentation
Conference Call | November 29, 2023
Presentation of unblinded topline data from the Phase 3 trial of NE3107 in patients with Mild to Moderate Alzheimer’s Disease
Cantor Health Care Conference
Cuong Do, BioVie’s President and CEO, discusses the company’s program at the Cantor Global Healthcare Conference.
Virtual KOL Event
Featuring Dr. Steven Arnold, Harvard Medical School and Massachusetts General Hospital for a discussion on inflammation and the context for the anticipated Phase 3 topline data readout.
RedChip Money Report®
RedChip’s Money Report, Craig Belsford, interviews BioVie’s President & CEO, Cuong Do
Exclusive Interview • December 16, 2022
Proactive with Steve Darling
Proactive Investors interviews BioVie’s Chief Medical Officer, Dr. Joseph Palumbo
Exclusive Interview • December 12, 2022
Traders News Source Interview
Toni Loudenbeck of Traders News Source interviews BioVie President & CEO, Cuong Do
Exclusive Interview • December 12, 2022
Varney & Co. Welcomes BioVie to NY Studio
Fox Business’s, Varney & Co. Interviews BioVie President & CEO, Cuong Do
Exclusive Interview • December 7, 2022
Proactive with Natalie Stoberman
Proactive Investors interviews BioVie’s President & CEO, Cuong Do to discuss latest AD & PD news
Exclusive Interview • December 6, 2022
Innovators with Jane King
LilaMax Media’s, Jane King interviews BioVie’s President & CEO, Cuong Do at NASDAQ
Exclusive Interview • December 4, 2022
BioVie KOL Webinar
Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease.
Webinar • October 26, 2021
(Requires Login)
American Diabetes Association Thought Leadership Series
Understanding the Links Between Insulin Resistance and Alzheimer’s.
NE3107 Video • June 2021
BioVie KOL Webinar
Advanced Liver Cirrhosis – BIV-201 Phase 2b Clinical Trial Update.
Webinar • November 11, 2021
(Requires Login)